Randomized trial: Remdesivir vs. standard care in patients with moderate COVID-19

Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial – JAMA

Editorial: Efficacy of Remdesivir in COVID-19

Commentaries: Study: Remdesivir doesn’t boost outcomes in moderate pneumonia from COVID-19 – UPI AND New Remdesivir Study Shows the Trouble With Bad Science – The Wire

Commentary on Twitter

Remdesivir….good editorial, concludes we don't know who to give it to, nor for how long, nor if it improves outcomes, nor whether, if it does, it does that beyond what dexamethasone or other corticosteroids do. https://t.co/Qi1dTSPcYi

— Dr. Tom Frieden (@DrTomFrieden) August 21, 2020